Home / Media / Webinars / Webinar – Advocacy in rare disease: A Fireside Chat with the U.S. Commissioner of Food and Drugs
Webinar

Webinar – Advocacy in rare disease: A Fireside Chat with the U.S. Commissioner of Food and Drugs

In this fireside chat with the FDA commissioner, viewers will learn more about the FDA’s commitment to addressing rare diseases and how they incentivize the development of treatments

The fifth webinar of the 2023 series aired November 15th and is available on demand. 

Register and watch 

About the webinar

We are pleased to welcome Robert M. Califf, Commissioner of Food and Drugs at the United States Food and Drug Administration (FDA), for a Fireside Chat about the intersection between the FDA and rare disease. This intimate and enlightening conversation will provide unique insights into the challenges and opportunities faced by individuals and organizations dedicated to advancing research and treatment options for rare diseases.

While each rare disease may affect only a small percentage of the population, collectively their impact is enormous, with more than 7,000 rare diseases affecting 1 in 10 people. Patients, families, caregivers, and advocacy groups work tirelessly to raise awareness, accelerate research, and navigate the complex regulatory landscape. In this Fireside Chat, we will explore how the FDA, as the regulatory authority for medical products in the United States, collaborates with these advocates to ensure timely and safe access to innovative therapies for rare disease patients.

Watching this Science Webinar, viewers will:

  • Learn about the FDA’s commitment to addressing rare diseases and how they incentivize the development of treatments
  • Hear the Commissioner speak to FDA collaborations with international regulatory agencies, patient advocacy groups, and individuals with rare disease
  • Explore recent technological advances that are streamlining the regulatory process.

This webinar will last for approximately 30 minutes.

Panel:

 

Robert M. Califf, M.D. (US Food and Drugs Administration)
Erika Gebel Berg, Ph.D. (Science/AAAS, Washington, DC)